Log in

DURECT Stock Forecast, Price & News

-0.07 (-3.98 %)
(As of 09/23/2020 12:00 AM ET)
Today's Range
Now: $1.69
50-Day Range
MA: $1.96
52-Week Range
Now: $1.69
Volume1.06 million shs
Average Volume1.45 million shs
Market Capitalization$338.98 million
P/E RatioN/A
Dividend YieldN/A
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for experimental research in mice, rats, and other laboratory animals; and a range of biodegradable polymers for pharmaceutical and medical device clients for use as raw materials in their products under the LACTEL brand. Its product pipeline consists of multiple investigational drug candidates in development, such as DUR-928, an endogenous, orally bioavailable small molecule that is in Phase I and II development stage to play a regulatory role in lipid homeostasis, inflammation, and cell survival. The company's oral and injectable delivery technologies are designed to enable new indications and enhanced attributes for small-molecule and biologic drugs, including POSIMIR, an investigational analgesic product intended to deliver bupivacaine to provide up to 3 days of pain relief after surgery. DURECT Corporation markets and sells its ALZET and LACTEL product lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; Santen Pharmaceutical Co., Ltd.; Sandoz AG; and Zogenix, Inc. DURECT Corporation was founded in 1998 and is headquartered in Cupertino, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.50 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:DRRX



Sales & Book Value

Annual Sales$29.56 million
Book Value$0.12 per share


Net Income$-20,580,000.00


Market Cap$338.98 million
Next Earnings Date11/2/2020 (Estimated)
-0.07 (-3.98 %)
(As of 09/23/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive DRRX News and Ratings via Email

Sign-up to receive the latest news and ratings for DRRX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

DURECT (NASDAQ:DRRX) Frequently Asked Questions

How has DURECT's stock been impacted by Coronavirus (COVID-19)?

DURECT's stock was trading at $1.65 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, DRRX stock has increased by 2.4% and is now trading at $1.69.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of DURECT?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DURECT in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for DURECT

When is DURECT's next earnings date?

DURECT is scheduled to release its next quarterly earnings announcement on Monday, November 2nd 2020.
View our earnings forecast for DURECT

How were DURECT's earnings last quarter?

DURECT Co. (NASDAQ:DRRX) posted its earnings results on Monday, August, 3rd. The specialty pharmaceutical company reported $0.07 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.02 by $0.05. The specialty pharmaceutical company had revenue of $25.84 million for the quarter, compared to the consensus estimate of $19.76 million. DURECT had a negative return on equity of 7.69% and a negative net margin of 3.66%.
View DURECT's earnings history

What price target have analysts set for DRRX?

5 brokerages have issued 12 month price objectives for DURECT's shares. Their forecasts range from $5.00 to $7.00. On average, they expect DURECT's share price to reach $5.75 in the next twelve months. This suggests a possible upside of 240.2% from the stock's current price.
View analysts' price targets for DURECT

Are investors shorting DURECT?

DURECT saw a decline in short interest in the month of August. As of August 31st, there was short interest totaling 9,520,000 shares, a decline of 13.5% from the August 15th total of 11,000,000 shares. Based on an average daily trading volume, of 1,720,000 shares, the days-to-cover ratio is currently 5.5 days.
View DURECT's Short Interest

Who are some of DURECT's key competitors?

What other stocks do shareholders of DURECT own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DURECT investors own include Geron (GERN), Cassava Sciences (SAVA), Novavax (NVAX), VBI Vaccines (VBIV), Amarin (AMRN), Catalyst Pharmaceuticals (CPRX), Inovio Pharmaceuticals (INO), MannKind (MNKD), Matinas BioPharma (MTNB) and Verastem (VSTM).

Who are DURECT's key executives?

DURECT's management team includes the following people:
  • Dr. James E. Brown, Co-Founder, CEO, Pres & Director (Age 62)
  • Mr. Matthew J. Hogan, CFO & Sec. (Age 59)
  • Ms. Judy R. Joice, Sr. VP of Operations & Corp. Quality Assurance (Age 62)
  • Mr. Michael H. Arenberg, Chief Financial Officer (Age 49)
  • Dr. John W. Gibson B.S., M.S., VP of Birmingham Operations & Principal Scientist

What is DURECT's stock symbol?

DURECT trades on the NASDAQ under the ticker symbol "DRRX."

Who are DURECT's major shareholders?

DURECT's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (5.00%), Ingalls & Snyder LLC (3.97%), Beirne Wealth Consulting Services LLC (1.01%), Two Sigma Advisers LP (0.58%), Jefferies Group LLC (0.51%) and Gagnon Securities LLC (0.50%). Company insiders that own DURECT stock include First Eagle Investment Managem, James E Brown, Jon S Saxe, Judy R Joice, Lp Bleichroeder and Michael Arenberg.
View institutional ownership trends for DURECT

Which major investors are selling DURECT stock?

DRRX stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Tocqueville Asset Management L.P., Gagnon Securities LLC, Bank of America Corp DE, WINTON GROUP Ltd, Ingalls & Snyder LLC, and Ironwood Investment Management LLC. Company insiders that have sold DURECT company stock in the last year include Judy R Joice, and Lp Bleichroeder.
View insider buying and selling activity for DURECT

Which major investors are buying DURECT stock?

DRRX stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Nuveen Asset Management LLC, Bank of New York Mellon Corp, Swiss National Bank, Charles Schwab Investment Management Inc., State of Wisconsin Investment Board, California State Teachers Retirement System, and Mackay Shields LLC. Company insiders that have bought DURECT stock in the last two years include First Eagle Investment Managem, James E Brown, Jon S Saxe, Lp Bleichroeder, and Michael Arenberg.
View insider buying and selling activity for DURECT

How do I buy shares of DURECT?

Shares of DRRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is DURECT's stock price today?

One share of DRRX stock can currently be purchased for approximately $1.69.

How big of a company is DURECT?

DURECT has a market capitalization of $338.98 million and generates $29.56 million in revenue each year. The specialty pharmaceutical company earns $-20,580,000.00 in net income (profit) each year or ($0.12) on an earnings per share basis. DURECT employs 88 workers across the globe.

What is DURECT's official website?

The official website for DURECT is www.durect.com.

How can I contact DURECT?

DURECT's mailing address is 10260 BUBB RD, CUPERTINO CA, 95014. The specialty pharmaceutical company can be reached via phone at 408-777-1417 or via email at m[email protected]

This page was last updated on 9/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.